Jie-du granule preparation for the treatment of advanced hepatocellular carcinoma: a retrospective cohort study of 177 patients

L.Y. Chen; X.F. Zhai; Z. Chen; J.F. Zhu; P.A. Qian; H.T. Zhao; C.Q. Ling

doi:10.18632/oncotarget.12887

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Jie-du granule preparation for the treatment of advanced hepatocellular carcinoma: a retrospective cohort study of 177 patients

L.Y. Chen, X.F. Zhai, Z. Chen, J.F. Zhu, P.A. Qian, H.T. Zhao and C.Q. Ling _

PDF | HTML | How to cite

Oncotarget. 2017; 8:30471-30476. https://doi.org/10.18632/oncotarget.12887

Metrics: PDF 1570 views | HTML 1671 views | ?

Abstract

L.Y. Chen1, X.F. Zhai1,*, Z. Chen1, J.F. Zhu2, P.A. Qian2, H.T. Zhao1 and C.Q. Ling1

1 Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China

2 Department of Liver Disease, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China

* These authors have contributted equally to this work

Correspondence to:

C.Q. Ling, email:

Keywords: hepatocellular carcinoma, Jie-du granule, best supportive treatment, retrospective cohort study

Received: July 28, 2016 Accepted: October 19, 2016 Published: October 25, 2016

Abstract

Objective: To compare the clinical efficacy of Jie-du granule preparation versus best supportive treatment in patients with advanced hepatocellular carcinoma.

Methods: A retrospective cohort study was carried out in patients with advanced liver cancer. Patients were divided into Jie-du granule treatment (JD) and best supportive treatment (BST) groups. The main outcomes included median overall survival time.

Results: A total of 177 patients with Barcelona Clinic Liver Cancer stage C receiving JD granule treatment or BST were enrolled between January 2012 and December 2014. The overall median survival time was 6.2 months (95% confidence interval [CI] 4.546-7.854) in the JD group versus 4 months (95% CI 3.471-4.529) in the BST group. Significant independent risk factors were alpha-fetoprotein (P = 0.048), Child-Pugh class (P = 0.005), vascular invasion (P = 0.003), and extrahepatic metastasis (P = 0.0018). For patients with two or fewer of these independent risk factors, the overall median survival of those treated with JD was significantly longer than that of patients receiving BST (P < 0.05).

Conclusion: Jie-du granule preparation may prolong survival of patients with advanced HCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12887

Publication Alerts

Clinical Research Papers:

Jie-du granule preparation for the treatment of advanced hepatocellular carcinoma: a retrospective cohort study of 177 patients

Abstract